Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Research

Bristol-Myers Squibb is a pharmaceutical company dedicated to the research, development, and commercialization of treatments for a wide array of medical conditions. Its primary therapeutic domains include cardiovascular health, oncology, and immunological disorders. A significant strategic emphasis for the firm is immuno-oncology, an area where it has established itself as a leading innovator in developing new drugs. The company generates approximately 70% of its total revenue from the United States, indicating a considerably higher reliance on the American market compared to many of its industry counterparts.

Market snapshot

Symbol
BMYMP
Price
$400
Day change
-57.46%
Market cap
$110.3B
P/E ratio
15.17x
52-week range
400-1050
Sector
Healthcare
Industry
Drug Manufacturers - General

Peer companies

  • AstraZeneca PLC (AZNCF)
  • Bayer AG (BAYRY)
  • Chugai Pharmaceutical Co., Ltd. (CHGCF)
  • Chugai Pharmaceutical Co., Ltd. (CHGCY)
  • GSK plc (GLAXF)
  • Novartis AG (NVSEF)
  • Roche Holding AG (RHHBF)
  • Roche Holding AG (RHHBY)

Recent insider activity

  • Haller Julia A — M-Exempt (20460 shares) on 2026-06-15
  • Haller Julia A — M-Exempt (20460 shares) on 2026-06-15
  • Short Bartie Wendy — M-Exempt (8040 shares) on 2026-06-03
  • Short Bartie Wendy — F-InKind (3876 shares) on 2026-06-03
  • Short Bartie Wendy — M-Exempt (8040 shares) on 2026-06-03

Open Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.